# Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System

> **NCT02010905** · PHASE2 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 120 (estimated)

## Conditions studied

- Tetralogy of Fallot
- Heart Defects, Congenital
- Ventricular Dysfunction, Right

## Interventions

- **DRUG:** Losartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02010905
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010905, "Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02010905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*